These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24811026)

  • 1. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.
    Tsabouri S; Tseretopoulou X; Priftis K; Ntzani EE
    J Allergy Clin Immunol Pract; 2014; 2(3):332-40.e1. PubMed ID: 24811026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis.
    Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
    Rhinology; 2021 Dec; 59(6):501-510. PubMed ID: 34714895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
    Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
    BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
    Jat KR; Walia DK; Khairwa A
    Cochrane Database Syst Rev; 2013 Sep; (9):CD010288. PubMed ID: 24043500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Yu C; Wang K; Cui X; Lu L; Dong J; Wang M; Gao X
    Am J Rhinol Allergy; 2020 Mar; 34(2):196-208. PubMed ID: 31672020
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.
    Storms W; Bowdish MS; Farrar JR
    Allergy Asthma Proc; 2012; 33(2):172-7. PubMed ID: 22525394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab: a monoclonal anti-IgE antibody.
    Belliveau PP
    MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE treatment in allergic rhinitis.
    Bayar Muluk N; Bafaqeeh SA; Cingi C
    Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.